Peroxisome Proliferator-Activated Receptor (PPAR): Balance for survival in parasitic infections

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Chan, Marion M ^a   Evans, Kyle W ^a   Moore, Andrea R ^a   Fong, Dunne ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b State University of New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CURCUMIN; CYTOKINE; FATTY ACID; NUCLEAR FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PRAZIQUANTEL; ROSIGLITAZONE; LIGAND;

ARACHIDONIC ACID METABOLISM; ARTICLE; BRAIN MALARIA; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIVER FIBROSIS; MACROPHAGE ACTIVATION; MALARIA; NONHUMAN; PARASITOSIS; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VISCERAL LEISHMANIASIS; ANIMAL; IMMUNE EVASION; IMMUNOLOGY; METABOLISM; REVIEW;

ANIMALS; HUMANS; IMMUNE EVASION; IMMUNITY; LIGANDS; PARASITIC DISEASES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 77954612396     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/828951     Document Type: Article

References (63)

1. L. Michalik, J. Auwerx, J. P. Berger, et al., "International union of pharmacology. LXI. Peroxisome proliferator-activated receptors," Pharmacological Reviews, vol. 58, no. 4, pp. 726-741, 2006. (Pubitemid 44833742)
2. A. Zieleniak, M. Wójcik, and L. A. Woźniak, "Structure and physiological functions of the human peroxisome proliferator-activated receptor γ," Archivum Immunologiae et Therapiae Experimentalis, vol. 56, no. 5, pp. 331-345, 2008.
3. Y. Zhu, C. Qi, J. R. Korenberg, et al., "Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms," Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 17, pp. 7921-7925, 1995.
4. H. Sundvold and S. Lien, "Identification of a novel peroxisome proliferator-activated receptor (PPAR) γ promoter in man and transactivation by the nuclear receptor RORα1," Biochemical and Biophysical Research Communications, vol. 287, no. 2, pp. 383-390, 2001. (Pubitemid 32917609)
5. V. Zoete, A. Grosdidier, and O. Michielin, "Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators," Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 915-925, 2007. (Pubitemid 47208545)
6. P. Tontonoz and B. M. Spiegelman, "Fat and beyond: the diverse biology of PPARγ," Annual Review of Biochemistry, vol. 77, pp. 289-312, 2008.
7. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, "From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions," Progress in Lipid Research, vol. 45, no. 2, pp. 120-159, 2006. (Pubitemid 43248732)
8. N. S. Tan, L. Michalik, B. Desvergne, and W. Wahli, "Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes," Journal of Steroid Biochemistry and Molecular Biology, vol. 93, no. 2-5, pp. 99-105, 2005. (Pubitemid 40602481)
9. D. S. Straus and C. K. Glass, "Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms," Trends in Immunology, vol. 28, no. 12, pp. 551-558, 2007. (Pubitemid 350101420)
10. F. O. Martinez, L. Helming, and S. Gordon, "Alternative activation of macrophages: an immunologic functional perspective," Annual Review of Immunology, vol. 27, pp. 451-483, 2009.
11. J. L. Reyes and L. I. Terrazas, "The divergent roles of alternatively activated macrophages in helminthic infections," Parasite Immunology, vol. 29, no. 12, pp. 609-619, 2007. (Pubitemid 350179388)
12. G. Raes, A. Beschin, G. H. Ghassabeh, and P. De Baetselier, "Alternatively activated macrophages in protozoan infections," Current Opinion in Immunology, vol. 19, no. 4, pp. 454-459, 2007. (Pubitemid 47284853)
13. W. Noël, G. Raes, G. H. Ghassabeh, et al., "Alternatively activated macrophages during parasite infections," Trends in Parasitology, vol. 20, no. 3, pp. 126-133, 2004. (Pubitemid 38264445)
14. S. A. Kliewer, B. M. Forman, B. Blumberg, et al., "Differential expression and activation of a family of murine peroxisome proliferator- activated receptors," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355-7359, 1994. (Pubitemid 24226862)
15. M. E. Greene, B. Blumberg, O. W. McBride, et al., "Isolation of the human peroxisome proliferator activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping," Gene Expression, vol. 4, no. 4-5, pp. 281-299, 1995.
16. C. Jiang, A. T. Ting, and B. Seed, "PPAR-γ agonists inhibit production of monocyte inflammatory cytokines," Nature, vol. 391, no. 6662, pp. 82-86, 1998. (Pubitemid 28079219)
17. M. Ricote, J. T. Huang, J. S. Welch, and C. K. Glass, "The peroxisome proliferator-activated receptor (PPARγ) as a regulator of monocyte/macrophage function," Journal of Leukocyte Biology, vol. 66, no. 5, pp. 733-739, 1999. (Pubitemid 29532032)
18. L. Széles, D. Töröcsik, and L. Nagy, "PPARγ in immunity and inflammation: cell types and diseases," Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1014-1030, 2007. (Pubitemid 47202035)
19. E. Rigamonti, G. Chinetti-Gbaguidi, and B. Staels, "Regulation of macrophage functions by PPAR-α, PPAR-γ, and LXRs in mice and men," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 6, pp. 1050-1059, 2008.
20. X. Y. Yang, L. H. Wang, and W. L. Farrar, "A role for PPARγ in the regulation of cytokines in immune cells and cancer," PPAR Research, vol. 2008, Article ID 961753, 12 pages, 2008.
21. Y. Yang, A. R. Gocke, A. Lovett-Racke, P. D. Drew, and M. K. Racke, "PPAR α regulation of the immune response and autoimmune encephalomyelitis," PPAR Research, vol. 2008, Article ID 546753, 6 pages, 2008.
22. J. T. Huang, J. S. Welch, M. Ricote, et al., "Interleukin-4- dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase," Nature, vol. 400, no. 6742, pp. 378-382, 1999. (Pubitemid 29344205)
23. M.-S. Yang, K.-A. Ji, S.-B. Jeon, et al., "Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: implications for death of activated microglia," Journal of Immunology, vol. 177, no. 2, pp. 1323-1329, 2006. (Pubitemid 44036639)
24. T. Shimizu, "Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation," Annual Review of Pharmacology and Toxicology, vol. 49, pp. 123-150, 2009.
25. R. B. Clark, "The role of PPARs in inflammation and immunity," Journal of Leukocyte Biology, vol. 71, no. 3, pp. 388-400, 2002.
26. R. A. Daynes and D. C. Jones, "Emerging roles of PPARs in inflammation and immunity," Nature Reviews Immunology, vol. 2, no. 10, pp. 748-759, 2002. (Pubitemid 37328715)
27. A. Castrillo and P. Tontonoz, "Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation," Annual Review of Cell and Developmental Biology, vol. 20, pp. 455-480, 2004. (Pubitemid 39488646)
28. S. J. Bensinger and P. Tontonoz, "Integration of metabolism and inflammation by lipid-activated nuclear receptors," Nature, vol. 454, no. 7203, pp. 470-477, 2008.
29. A. Szanto and L. Nagy, "The many faces of PPARγ: anti-inflammatory by any means?" Immunobiology, vol. 213, no. 9-10, pp. 789-803, 2008.
30. S. Dasgupta, A. Roy, M. Jana, D. M. Hartley, and K. Pahan, "Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-α," Molecular Pharmacology, vol. 72, no. 4, pp. 934-946, 2007. (Pubitemid 47481416)
31. T. Hänscheid, T. J. Egan, and M. P. Grobusch, "Haemozoin: from melatonin pigment to drug target, diagnostic tool, and immune modulator," Lancet Infectious Diseases, vol. 7, no. 10, pp. 675-685, 2007. (Pubitemid 47454562)
32. O. A. Skorokhod, M. Alessio, B. Mordmüller, P. Arese, and E. Schwarzer, "Hemozoin (malarial pigment) inhibits differentiation and maturation of human monocyte-derived dendritic cells: a peroxisome proliferator-activated receptor-γ-mediated effect," Journal of Immunology, vol. 173, no. 6, pp. 4066-4074, 2004. (Pubitemid 39280771)
33. B. C. Urban and S. Todryk, "Malaria pigment paralyzes dendritic cells," Journal of Biology, vol. 5, no. 2, article 4, 2006.
34. M. M. Chen, L. Shi, and D. J. Sullivan Jr., "Haemoproteus and Schistosoma synthesize heme polymers similar to Plasmod-ium hemozoin and β-hematin," Molecular and Biochemical Parasitology, vol. 113, no. 1, pp. 1-8, 2001. (Pubitemid 32209277)
35. M. F. Oliveira, S. W. Kycia, A. Gomez, et al., "Structural and morphological characterization of hemozoin produced by Schistosoma mansoni and Rhodnius prolixus," FEBS Letters, vol. 579, no. 27, pp. 6010-6016, 2005. (Pubitemid 41546238)
36. M. D. Carter, S. Reese Harry, and D. W. Wright, "Identification of hydroxyeicosatetraenoic acid components of schistosomal hemozoin," Biochemical and Biophysical Research Communications, vol. 363, no. 3, pp. 867-872, 2007. (Pubitemid 47513710)
37. T. J. Egan, "Haemozoin formation," Molecular and Biochemical Parasitology, vol. 157, no. 2, pp. 127-136, 2008.
38. G. L. Bannenberg, J. Aliberti, S. Hong, A. Sher, and C. Ser-han, "Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis," Journal of Experimental Medicine, vol. 199, no. 4, pp. 515-523, 2004. (Pubitemid 38233835)
39. W. R. Henderson Jr. and E. Y. Chi, "Cytotoxic activity of 13-hydroxyoctadecadienoic acid against Toxoplasma gondii," Parasitology, vol. 105, no. 3, pp. 343-347, 1992.
40. D. Sacks and N. Noben-Trauth, "The immunology of susceptibility and resistance to Leishmania major in mice," Nature Reviews Immunology, vol. 2, no. 11, pp. 845-858, 2002. (Pubitemid 37328707)
41. J. I. Odegaard, R. R. Ricardo-Gonzalez, and M. H. Goforth, "Macrophage-specific PPARγ controls alternative activation and improves insulin resistance," Nature, vol. 447, no. 7148, pp. 1116-1120, 2007. (Pubitemid 47014427)
42. N. Adapala and M. M. Chan, "Long-term use of an anti-inflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model," Laboratory Investigation, vol. 88, no. 12, pp. 1329-1339, 2008.
43. A. Gallardo-Soler, C. Gómez-Nieto, M. L. Campo, et al., "Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-γ/δ-mediated effect that links lipid metabolism and immunity," Molecular Endocrinology, vol. 22, no. 6, pp. 1394-1402, 2008. (Pubitemid 351786999)
44. X.-Q. Wei, I. G. Charles, A. Smith, et al., "Altered immune responses in mice lacking inducible nitric oxide synthase," Nature, vol. 375, no. 6530, pp. 408-411, 1995.
45. H. W. Murray and F. Nathan, "Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani," Journal of Experimental Medicine, vol. 189, no. 4, pp. 741-746, 1999. (Pubitemid 29193376)
46. M. M. Chan, N. S. Adapala, and D. Fong, "Curcumin overcomes the inhibitory effect of nitric oxide on Leishmania," Parasitology Research, vol. 96, no. 1, pp. 49-56, 2005. (Pubitemid 40674924)
47. A. Berry, P. Balard, A. Coste, et al., "IL-13 induces expression of CD36 in human monocytes through PPARγ activation," European Journal of Immunology, vol. 36, no. 6, pp. 1642-1652, 2007. (Pubitemid 46939499)
48. A. Nencioni, F. Grunebach, A. Zobywlaski, C. Denzlinger, W. Brugger, and P. Brossart, "Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor γ," Journal of Immunology, vol. 169, no. 3, pp. 1228-1235, 2002. (Pubitemid 34809163)
49. L. Serghides, T. G. Smith, S. N. Patel, and K. C. Kain, "CD36 and malaria: friends or foes?" Trends in Parasitology, vol. 19, no. 10, pp. 461-469, 2003. (Pubitemid 38366143)
50. T. Areschoug and S. Gordon, "Scavenger receptors: role in innate immunity and microbial pathogenesis," Cellular Microbiology, vol. 11, no. 8, pp. 1160-1169, 2009.
51. R. L. Silverstein and M. Febbraio, "CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior," Science Signaling, vol. 2, no. 72, 2009.
52. L. Serghides and K. C. Kain, "Peroxisome proliferator-activated receptor γ-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNFα secretion by monocytes/macrophages," Journal of Immunology, vol. 166, no. 11, pp. 6742-6748, 2001. (Pubitemid 32467218)
53. T. G. Smith, L. Serghides, S. N. Patel, M. Febbraio, R. L. Silverstein, and K. C. Kain, "CD36-mediated nonopsonic phagocytosis of erythrocytes infected with stage I and IIA gametocytes of Plasmodium falciparum," Infection andImmu-nity, vol. 71, no. 1, pp. 393-400, 2003. (Pubitemid 36026043)
54. S. N. Patel, L. Serghides, T. G. Smith, et al., "CD36 mediates the phagocytosis of Plasmodium falciparum-infected erythrocytes by rodent macrophages," Journal of Infectious Diseases, vol. 189, no. 2, pp. 204-213, 2004. (Pubitemid 38147243)
55. K. Ayi, S. N. Patel, L. Serghides, T. G. Smith, and K. C. Kain, "Nonopsonic phagocytosis of erythrocytes infected with ring-stage Plasmodium falciparum," Infection and Immunity, vol. 73, no. 4, pp. 2559-2563, 2005. (Pubitemid 40470863)
56. L. Serghides and K. C. Kain, "Peroxisome proliferator-activated receptor γ and retinoid X receptor agonists have minimal effects on the interaction of endothelial cells with Plasmodium falciparum-infected erythrocytes," Infection and Immunity, vol. 73, no. 2, pp. 1209-1213, 2005. (Pubitemid 40165783)
57. L. Serghides, S. N. Patel, K. Ayi, et al., "Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria," Journal of Infectious Diseases, vol. 199, no. 10, pp. 1536-1545, 2009.
58. D. R. Herbert, C. Hölscher, M. Mohrs, et al., "Alternative macrophage activation is essential for survival during schis-tosomiasis and downmodulates T helper 1 responses and immunopathology," Immunity, vol. 20, no. 5, pp. 623-635, 2004. (Pubitemid 38659504)
59. P. Gervois, J. C. Fruchart, and B. Staels, "Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors," Nature Clinical Practice Endocrinology and Metabolism, vol. 3, no. 2, pp. 145-156, 2007. (Pubitemid 46146967)
60. H. Chen, Y. W. He, W. Q. Liu, and J. H. Zhang, "Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum," World Journal of Gastroenterology, vol. 14, no. 18, pp. 2905-2911, 2008.
61. F. Ondrey, "Peroxisome proliferator-activated receptor γ pathway targeting in carcinogenesis: implications for chemopre-vention," Clinical Cancer Research, vol. 15, no. 1, pp. 2-8, 2009.
62. P. Balakumar, M. Rose, S. S. Ganti, et al., "PPAR dual agonists: are they opening Pandora's box?" Pharmacological Research, vol. 56, no. 2, pp. 91-98, 2007. (Pubitemid 47304493)
63. A. Rubenstrunk, R. Hanf, D. W. Hum, J.-C. Fruchart, and B. Staels, "Safety issues and prospects for future generations of PPAR modulators," Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1065-1081, 2007. (Pubitemid 47208546)